SBIR Phase II: Absolute protein quantitation in in vitro diagnostics for gut inflammation

SBIR II 期:肠道炎症体外诊断中的绝对蛋白质定量

基本信息

  • 批准号:
    2242174
  • 负责人:
  • 金额:
    $ 99.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
    Cooperative Agreement
  • 财政年份:
    2024
  • 资助国家:
    美国
  • 起止时间:
    2024-03-15 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to advance clinical methods that address the extensive physiological variation that is age- and race-dependent. Well-publicized over the last few decades is the lack of healthcare solutions for diseases in preemie babies, who are born to mothers with significant socioeconomic inequalities. Case in point, necrotizing enterocolitis (NEC) is a common and often fatal gastrointestinal, or gut, emergency in premature infants that disproportionately affects African American babies. The disease has not only confounded doctors and nurses for 200 years, but also these neonatal emergencies are also frightening to almost all preemie care providers due to its high mortality rate. Its healthcare in the US requires $3 billion annually due to repeated x-ray testing, surgery, longer hospital stays, and long-term complications of its survivors. An early and accurate diagnostic test for NEC would be a disruptive paradigm shift in preemie intensive care: it would enable medical intervention to be more effective, reduce risk of disease progression, decrease medical care expenses by hundreds of millions annually, and lower mortality.The proposed project will develop requisite reagents for a diagnostic test that will enable detection of infant proteins that play a role in gut health. Absolute quantitation is a prerequisite for data interpretation and validation between experiments, laboratories, and testing platforms. Research objectives are directed toward critical technical hurdles: (1) determination of optimal reference standard to quantitate host biomolecules in clinical settings and (2) understanding the usage limitations of these reference standards in the background of high variation in the human population. Native and recombinant candidates will be compared and analyzed with various methods. Anticipated results are reference standards that are age-specific for diagnostic use in the most fragile and smallest patients and that are acceptable to regulatory stakeholders.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
这个小企业创新研究 (SBIR) 第二阶段项目的更广泛影响是推进临床方法,解决与年龄和种族相关的广泛生理变化。过去几十年来,众所周知,早产儿疾病缺乏医疗保健解决方案,这些早产儿的母亲面临着严重的社会经济不平等。举例来说,坏死性小肠结肠炎 (NEC) 是早产儿常见且往往致命的胃肠道急症,对非裔美国婴儿的影响尤为严重。这种疾病不仅让医生和护士困惑了 200 年,而且这些新生儿紧急情况也因其高死亡率而令几乎所有早产儿护理人员感到恐惧。 由于反复的 X 射线检查、手术、较长的住院时间以及幸存者的长期并发症,其在美国的医疗保健每年需要 30 亿美元。对 NEC 进行早期准确的诊断测试将是早产儿重症监护领域的颠覆性范式转变:它将使医疗干预更加有效,降低疾病进展的风险,每年减少数亿的医疗费用,并降低死亡率。拟议的项目将开发诊断测试所需的试剂,从而能够检测在肠道健康中发挥作用的婴儿蛋白质。 绝对定量是实验、实验室和测试平台之间数据解释和验证的先决条件。研究目标针对关键的技术障碍:(1) 确定临床环境中定量宿主生物分子的最佳参考标准;(2) 了解这些参考标准在人群高度变异的背景下的使用限制。将使用各种方法对天然和重组候选物进行比较和分析。 预期结果是参考标准,针对最脆弱和最小的患者进行诊断,并且可以为监管利益相关者所接受。该奖项反映了 NSF 的法定使命,并通过使用基金会的智力优点和更广泛的影响审查标准进行评估,被认为值得支持。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rebecca Buckley其他文献

A Single-Center Review of Severe Combined Immune Deficiency (SCID) Newborn Screening (NBS) Data in the Neonatal Intensive Care Unit (NICU)
新生儿重症监护病房(NICU)中严重联合免疫缺陷(SCID)新生儿筛查(NBS)数据的单中心回顾
  • DOI:
    10.1016/j.jaci.2022.12.660
  • 发表时间:
    2023-02-01
  • 期刊:
  • 影响因子:
    11.200
  • 作者:
    Geoffrey Hall;Trevor Burt;Kimberley Fisher;Rick Pittman;John Sleasman;Rebecca Buckley;Michael Cotten;Talal Mousallem
  • 通讯作者:
    Talal Mousallem
34-OR: Impact of alloreactivity of killer Ig-like receptors in the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency
  • DOI:
    10.1016/j.humimm.2006.08.042
  • 发表时间:
    2006-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Michael D. Keller;Dong-Feng Chen;Nancy L. Reinsmoen;Na Liu;Rebecca Buckley
  • 通讯作者:
    Rebecca Buckley
Multivariate Data Analyses for Classifying Allosteric Inhibition in Human Eg5 Kinesin
  • DOI:
    10.1016/j.bpj.2009.12.888
  • 发表时间:
    2010-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Elizabeth D. Kim;Rebecca Buckley;Jessica Richard;Sarah Learman;Edward J. Wojcik;Richard Walker;Sunyoung Kim
  • 通讯作者:
    Sunyoung Kim
Crystal Structure of HsEg5 in Complex with S-trityl-L-cysteine
  • DOI:
    10.1016/j.bpj.2008.12.2617
  • 发表时间:
    2009-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Courtney L. Parke;Rebecca Buckley;Sunyoung Kim;David K. Worthylake
  • 通讯作者:
    David K. Worthylake
T-cell Exhaustion In Patients With Severe Combined Immunodeficiency Transplanted Without Conditioning OR Graft Versus Host Disease Prophylaxis
未进行预处理及移植物抗宿主病预防而行移植的重症联合免疫缺陷患者的T细胞耗竭
  • DOI:
    10.1016/j.jaci.2024.12.864
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
    11.200
  • 作者:
    Talal Mousallem;Geoffrey Hall;Cesar Lopez Angel;Roberta Parrott;Rebecca Buckley
  • 通讯作者:
    Rebecca Buckley

Rebecca Buckley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

Baryogenesis, Dark Matter and Nanohertz Gravitational Waves from a Dark Supercooled Phase Transition
  • 批准号:
    24ZR1429700
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
ATLAS实验探测器Phase 2升级
  • 批准号:
    11961141014
  • 批准年份:
    2019
  • 资助金额:
    3350 万元
  • 项目类别:
    国际(地区)合作与交流项目
地幔含水相Phase E的温度压力稳定区域与晶体结构研究
  • 批准号:
    41802035
  • 批准年份:
    2018
  • 资助金额:
    12.0 万元
  • 项目类别:
    青年科学基金项目
基于数字增强干涉的Phase-OTDR高灵敏度定量测量技术研究
  • 批准号:
    61675216
  • 批准年份:
    2016
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
基于Phase-type分布的多状态系统可靠性模型研究
  • 批准号:
    71501183
  • 批准年份:
    2015
  • 资助金额:
    17.4 万元
  • 项目类别:
    青年科学基金项目
纳米(I-Phase+α-Mg)准共晶的临界半固态形成条件及生长机制
  • 批准号:
    51201142
  • 批准年份:
    2012
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目
连续Phase-Type分布数据拟合方法及其应用研究
  • 批准号:
    11101428
  • 批准年份:
    2011
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
D-Phase准晶体的电子行为各向异性的研究
  • 批准号:
    19374069
  • 批准年份:
    1993
  • 资助金额:
    6.4 万元
  • 项目类别:
    面上项目

相似海外基金

SBIR Phase II: Innovative Two-Phase Cooling with Micro Closed Loop Pulsating Heat Pipes for High Power Density Electronics
SBIR 第二阶段:用于高功率密度电子产品的创新两相冷却微闭环脉动热管
  • 批准号:
    2321862
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
SBIR Phase II: Innovative Glass Inspection for Advanced Semiconductor Packaging
SBIR 第二阶段:先进半导体封装的创新玻璃检测
  • 批准号:
    2335175
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
SBIR Phase II: Intelligent Language Learning Environment
SBIR第二阶段:智能语言学习环境
  • 批准号:
    2335265
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
SBIR Phase II: FlashPCB Service Commercialization and AI Component Package Identification
SBIR第二阶段:FlashPCB服务商业化和AI组件封装识别
  • 批准号:
    2335464
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
SBIR Phase II: Thermally-optimized power amplifiers for next-generation telecommunication and radar
SBIR 第二阶段:用于下一代电信和雷达的热优化功率放大器
  • 批准号:
    2335504
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
SBIR Phase II: Sodium-Based Solid-State Batteries for Stationary Energy Storage
SBIR第二阶段:用于固定储能的钠基固态电池
  • 批准号:
    2331724
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
SBIR Phase II: A mesh-free, sling-free, minimally invasive treatment for stress urinary incontinence in women
SBIR II 期:无网、无吊带的微创治疗女性压力性尿失禁
  • 批准号:
    2233106
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
SBIR Phase II: Zero Trust Solution for Precision Medicine and Precision Health Data Exchanges
SBIR 第二阶段:精准医疗和精准健康数据交换的零信任解决方案
  • 批准号:
    2226026
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
SBIR Phase II: High-Performance Batteries to Decarbonize Heavy Duty Construction Equipment
SBIR 第二阶段:高性能电池使重型建筑设备脱碳
  • 批准号:
    2335320
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
SBIR Phase II: Technology for Stimulating the Herd Instinct of Livestock to Reduce Environmental Impact
SBIR第二阶段:刺激牲畜的群体本能以减少环境影响的技术
  • 批准号:
    2335554
  • 财政年份:
    2024
  • 资助金额:
    $ 99.97万
  • 项目类别:
    Cooperative Agreement
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了